Phase 2 study of add-on parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib: Final results

By sjmartinez • January 31, 2024

Yacoub A, Borate U, Rampal RK, Ali H, Wang ES, Gerds AT, Hobbs GS, Kremyanskaya M, Winton EF, O'Connell C, Goel S, Oh ST, Schiller GJ, McCloskey J, Palmer JM, Holmes H, Hager S, Assad A, Erickson-Viitanen S, Zhou F, Daver NG. Phase 2 study of add-on parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib: Final results. Blood Adv. 2024 Jan 30:bloodadvances.2023011620. doi: 10.1182/bloodadvances.2023011620. Epub ahead of print. PMID: 38290135.

Tags: Hematology/Oncology, Publications

Developing remote patient monitoring infrastructure using commercially available cloud platforms

Cao M, Ramezani R, Katakwar VK, Zhang W, Boda D, Wani M, Naeim A. Developing remote patient monitoring infrastructure using commercially available cloud platforms. Front[...]

INteractive survivorship program to improve health care REsources [INSPIRE]: A study protocol testing a digital intervention with stepped care telehealth to improve outcomes for adolescent and young adult survivors

Yi JC, Ballard S, Walsh C, Friedman DN, Ganz PA, Jacobs LA, Partridge AH, Mitchell SA, Leisenring WM, Syrjala KL, Baker KS. INteractive survivorship program[...]

Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma

Bitar R, Salem R, Finn R, Greten TF, Goldberg SN, Chapiro J. Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma. Radiology. 2024 Nov;313(2):e232875. doi:[...]